These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 33170753)

  • 1. Chemokine receptor CXCR4: An important player affecting the molecular-targeted drugs commonly used in hematological malignancies.
    Li L; Chai Y; Wu C; Zhao L
    Expert Rev Hematol; 2020 Dec; 13(12):1387-1396. PubMed ID: 33170753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
    Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
    Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.
    Peled A; Klein S; Beider K; Burger JA; Abraham M
    Cytokine; 2018 Sep; 109():11-16. PubMed ID: 29903571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth.
    Beider K; Begin M; Abraham M; Wald H; Weiss ID; Wald O; Pikarsky E; Zeira E; Eizenberg O; Galun E; Hardan I; Engelhard D; Nagler A; Peled A
    Exp Hematol; 2011 Mar; 39(3):282-92. PubMed ID: 21138752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies.
    Peng SB; Zhang X; Paul D; Kays LM; Ye M; Vaillancourt P; Dowless M; Stancato LF; Stewart J; Uhlik MT; Long H; Chu S; Obungu VH
    PLoS One; 2016; 11(3):e0150585. PubMed ID: 26954567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research advance on SDF-1/CXCR4 axis associated with hematological malignancies: review].
    Dai YY; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct; 14(5):1056-60. PubMed ID: 17096920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.
    Kuhne MR; Mulvey T; Belanger B; Chen S; Pan C; Chong C; Cao F; Niekro W; Kempe T; Henning KA; Cohen LJ; Korman AJ; Cardarelli PM
    Clin Cancer Res; 2013 Jan; 19(2):357-66. PubMed ID: 23213054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting MCL-1 in hematologic malignancies: Rationale and progress.
    Wei AH; Roberts AW; Spencer A; Rosenberg AS; Siegel D; Walter RB; Caenepeel S; Hughes P; McIver Z; Mezzi K; Morrow PK; Stein A
    Blood Rev; 2020 Nov; 44():100672. PubMed ID: 32204955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells.
    Broussas M; Boute N; Akla B; Berger S; Beau-Larvor C; Champion T; Robert A; Beck A; Haeuw JF; Goetsch L; Bailly C; Dumontet C; Matthes T; Corvaia N; Klinguer-Hamour C
    Mol Cancer Ther; 2016 Aug; 15(8):1890-9. PubMed ID: 27297868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
    Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
    Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.
    Magierowicz M; Tomowiak C; Leleu X; Poulain S
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):753-763. PubMed ID: 30190015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CXCR4: a new therapeutic target of the leukaemic cell? Role of the SDF-1/CXCR4 axis in acute myeloid leukaemia].
    Tavernier E; Aanei C; Solly F; Flandrin-Gresta P; Campos L; Guyotat D
    Bull Cancer; 2014 Jun; 101(6):593-604. PubMed ID: 24977448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies.
    Ogasawara K; Newhall K; Maxwell SE; Dell'Aringa J; Komashko V; Kilavuz N; Delarue R; Czuczman M; Sternas L; Rose S; Beach CL; Novick S; Zhou S; Palmisano M; Li Y
    Clin Pharmacokinet; 2020 Feb; 59(2):217-227. PubMed ID: 31332669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways.
    Pandey MK; Kale VP; Song C; Sung SS; Sharma AK; Talamo G; Dovat S; Amin SG
    Exp Hematol; 2014 Oct; 42(10):883-96. PubMed ID: 25034231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
    Scala S
    Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitors in the treatment of B-cell malignancies.
    Schenkein D
    Clin Lymphoma; 2002 Jun; 3(1):49-55. PubMed ID: 12141956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
    Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Tsakmaklis N; Kanan S; Castillo JJ; Treon SP
    Br J Haematol; 2015 Mar; 168(5):701-7. PubMed ID: 25371371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators.
    Beider K; Bitner H; Voevoda-Dimenshtein V; Rosenberg E; Sirovsky Y; Magen H; Canaani J; Ostrovsky O; Shilo N; Shimoni A; Abraham M; Weiss L; Milyavsky M; Peled A; Nagler A
    Biochem Pharmacol; 2019 Oct; 168():412-428. PubMed ID: 31325448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of mTOR inhibition in hematologic malignancies.
    Younes A; Samad N
    Oncologist; 2011; 16(6):730-41. PubMed ID: 21632450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.